Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: A multicenter, randomized, controlled trial

Pediatrics

Volumn 108, Issue 4, 2001, Pages 934-942

  Ohls, Robin K ^a,l   Ehrenkranz, Richard A ^b   Wright, Linda L ^k   Lemons, James A ^c   Korones, Sheldon B ^d   Stoll, Barbara J ^e   Stark, Ann R ^f   Shankaran, Seetha ^g   Donovan, Edward F ^h   Close, Nicole C ⁱ   Das, Abhik ^j  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b YALE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

^f HARVARD UNIVERSITY   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h UNIVERSITY OF CINCINNATI   (United States)

ⁱ GEORGE WASHINGTON UNIVERSITY   (United States)

^j RTI INTERNATIONAL   (United States)

^k EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^l UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Donor exposure; Intravenous iron; Neonate

Indexed keywords

ALPHA TOCOPHEROL; ERYTHROPOIETIN; FERRITIN; FOLIC ACID; IRON; PLACEBO;

AGE; ANEMIA; ARTICLE; BIRTH WEIGHT; BLOOD CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HUMAN; MALE; MULTICENTER STUDY; NEWBORN; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SUPPLEMENTATION; TREATMENT OUTCOME;

ANEMIA, NEONATAL; BLOOD TRANSFUSION; CHILD DEVELOPMENT; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; IRON; MALE; PLACEBOS;

EID: 17944365015     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.108.4.934     Document Type: Article

References (37)

1. The effect of erythropoietin on the transfusion requirements of preterm infants ≤750 grams: A randomized, double-blind, placebo-ontrolled study
2. Anemia of prematurity: Determinants of the erythropoietin response
3. Decreased response of plasma immunoreactive erythropoietin to "available oxygen" in anemia of prematurity
4. Circulating erythroid progenitors in the anemia of prematurity
5. Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the "anemia of prematurity"
6. Recombinant human erythropoietin in the treatment of the anemia of prematurity: Results of a double-blind, placebo-controlled study
7. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants
8. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very low birth weight infants
9. Follow-up of very low birth weight infants after erythropoierin treatment to prevent anemia of prematurity
10. The use of erythropoietin in neonates
11. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in parenteral nutrition solution
12. Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition
13. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin
14. An international classification for retinopathy of prematurity
15. Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1500 grams
16. Necrotizing enterocolitis: Treatment based on staging criteria
17. Erythropoietin, iron, and erythropoiesis
18. Reticulocyte cellular indices: A new approach in the diagnosis of anemias and monitoring of erythropoietic function
19. Endothelin concentrations in preterm infants treated with human recombinant erythropoietin
20. Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: A randomized trial
21. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo controlled trial
22. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin
23. Effect of enhanced erythropoiesis on iron absorption
24. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity
25. Increased incidence of gram-negative neonatal sepsis with intramuscular iron administration
26. Intramuscular iron-dextran and susceptibility of neonates to bacterial infections
27. Late-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network
28. Iron overload, free radical damage, and rhesus haemolytic disease
29. Blood transfusion. Iron load and retinopathy of prematurity
30. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994
31. Minimizing donor blood exposure in the neonatal intensive care unit. Current trends and future prospects
32. Changing patterns of red cell transfusion in very low birth weight infants
33. Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g
34. Prospective, randomized trial of the safety and efficacy of a limited donor exposure transfusion program for premature neonates
35. Feasibility and safety of AS-3 red blood cells for neonatal transfusions
36. Clinical performance of an in-line point-of-care monitor in neonates
37. Recombinant human erythropoietin vs transfusions in the treatment of the anemia of prematurity. A cost-benefit analysis